Reviva Pharmaceuticals Warrants
RVPHW
RVPHW was delisted on the 12th of December, 2025.
4 hedge funds and large institutions have $255K invested in Reviva Pharmaceuticals Warrants in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and 1 closing their positions.
41% more capital invested
Capital invested by funds: $181K → $255K (+$74.2K)
0.18% less ownership
Funds ownership: 0.89% → 0.71% (-0.18%)
20% less funds holding
Funds holding: 5 → 4 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$38.6K |
| 2 |
Walleye Trading
New York
|
-$28.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.67K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
Arena Investors
Purchase,
New York
| $149K | – | – | – |
|
|
2
Walleye Capital
New York
| $59.7K | -$38.6K | -20,598 | -38% |
|
|
3
Walleye Trading
New York
| $45.6K | -$28.5K | -15,232 | -37% |
|
|
NC
4
NewSquare Capital
Newtown Square,
Pennsylvania
| $886 | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| – | -$1.67K | -1,670 | Closed |
|
RVPHW Hedge Fund Activity: Q2 2023 in Review
4 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q2 2023, worth a combined $255K — up 41% from $181K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RVPHW and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.
The largest seller was Walleye Capital, cutting an estimated $38.6K.
- 4 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q2 2023, down from 5 in Q1 2023.
- Funds reported $255K of Reviva Pharmaceuticals Warrants stock for Q2 2023, up 41% quarter-over-quarter.
- 0 funds opened new Reviva Pharmaceuticals Warrants positions in Q2 2023 and 1 closed out, a net change of -1 holder.
- The largest Reviva Pharmaceuticals Warrants seller in Q2 2023 was Walleye Capital, an estimated $38.6K sold.
Based on aggregated 13F filings for Q2 2023.